x

Home

Patient Site
Order Form
EpicCare® Link™ Provider Portal
FAQs
Important Risk Information
Contact Us

CRC Screening Unmet Need
- CRC Landscape
- Impact of Choice
About Cologuard
Coverage and Support
Resources and Events

COVID-19 Response

No matter how far apart, patients are still within reach.

Take on suboptimal colorectal cancer screening rates

One Yes at a time

It’s time to get more patients screened

See the state of CRC screening

Cologuard^® may help you rule out CRC¹

View the data

Explore ordering options for Cologuard

How to order

Indication and Important Risk Information
Cologuard^® is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Cologuard is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

Positive Cologuard results should be referred to diagnostic colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

False positives and false negatives do occur. In a clinical study, 13% of patients without colorectal cancer or advanced adenomas received a positive result (false positive) and 8% of patients with cancer received a negative result (false negative). The clinical validation study was conducted in patients 50 years of age and older. Cologuard performance in patients ages 45 to 49 years was estimated by sub-group analysis of near-age groups.

Cologuard performance when used for repeat testing has not been evaluated or established. Rx only.

Reference: 1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.

CRC Landscape
Impact of Choice

Clinical Offer
Screening Comparison
Ease of Use
Appropriate Patients
National Guidelines

Coverage
Adherence Data
Specialized Support
EpicCare Link Provider Portal

How to Order
HCP Resources
Media Library
Events

About Exact Sciences
Contact Us
Terms of Use
Privacy Policy
Do Not Sell My Info

EXACT SCIENCES CORPORATION | 5505 Endeavor Lane Madison, Wisconsin 53719

Cologuard is a registered trademark of Exact Sciences Corporation in the U.S. and other countries. EpicCare and EpicCare Link are trademarks of Epic Systems Corporation.

©2020 Exact Sciences Corporation. All rights reserved. US.CG.4219-1 (v1.0)-February 2021